At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 66 enrolled
Drug / intervention
Greenlight XPS Laser +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia
In Brief
A Phase 4 clinical trial evaluating Greenlight XPS Laser and BiVAP Saline Vaporization of the prostate for Benign Prostatic Hyperplasia (BPH). Completed, enrolled 66 participants across 1 site.
Detailed Summary
This is a Phase 4, prospective, open-label, randomized study of Greenlight XPS Laser versus BiVAP Saline Vaporization of the prostate in men with symptomatic Benign Prostatic Hyperplasia (BPH). The study consists of a screening phase, treatment, followed by follow-up visits at 1 week, 4 weeks, 3 months, 6 months, and 12 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia (BPH)
CountriesUnited States
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionOct 2016
TodayJul 2026
First PostedDec 26, 2011
Enrollment StartDec 1, 2011
Primary CompletionOct 10, 2016
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 14.5 years ago
Interventions
Greenlight XPS Laserdevice
Treatment of BPH with Greenlight XPS laser
BiVAP Saline Vaporization of the prostatedevice
treatment of BPH with BiVAP Saline Vaporization